Showing 3641-3650 of 5847 results for "".
- Avene Partners With Dermatology Influencer at Ulta Beautyhttps://practicaldermatology.com/news/avene-partners-dermatology-influencer-ulta-beauty/2468359/Avene has announced a new partnership to bridge the gap between dermatological education and daily skincare, according to a news release. The French skincare brand is partnering with renowned boar
- Study: Excessive Sweating Linked to Sensitive Skinhttps://practicaldermatology.com/news/study-excessive-sweating-linked-sensitive-skin/2468351/A new study indicates a significant connection between primary hyperhidrosis, a condition of excessive sweating, and sensitive skin, where skin overreacts to stimuli like sweat and stress. The study was led by Practical Dermatology Editorial Board member Adam Friedman, MD, FAAD, chair of d
- LITE: Home-Based UV-B Phototherapy Matches Office-Based Treatment in Psoriasishttps://practicaldermatology.com/news/lite-home-based-uv-b-phototherapy-matches-office-based-treatment-psoriasis/2468330/Results from a new study suggest home-based narrowband UV-B phototherapy for psoriasis is noninferior to office-based treatment in achieving clear skin and improving patient quality of life. The researchers conducted the analysis across 42 dermatology practices in the United States and inc
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,
- Study Links Radioactive Iodine Therapy to Increased Melanoma Riskhttps://practicaldermatology.com/news/study-links-radioactive-iodine-therapy-increased-melnoma-risk/2468325/A new study found elevated risk of melanoma and other nonkeratinocyte skin cancers in patients with primary thyroid cancer who received radioactive iodine therapy, particularly in the head and neck region. In the JAMA Network Open article “Development of Melanoma and Other Nonkeratinocyte
- Baby Skincare Data at American Academy of Pediatricshttps://practicaldermatology.com/news/baby-skincare-data-american-academy-pediatrics/2468324/Kenvue Inc. will present new data demonstrating effective sleep and skin moisturization strategies for babies during the American Academy of Pediatrics (AAP) National Conference & Exhibition, set for September 27 through October 1 in Orlando, Florida. In addition to findings supporting
- Tralokinumab Data for H&N AD Presented at EADVhttps://practicaldermatology.com/news/tralokinumab-data-hn-ad-presented-eadv/2468323/Nine-month interim data from the TRACE study, showing that tralokinumab/tralokinumab-ldrm reduced the severity of moderate-to-severe atopic dermatitis (AD) in the head and neck region of the body (H&N), were shared through one of LEO Pharma’s five late-breaking oral presentations at the 33rd
- New Deuruxolitinib Data to Be Presented at EADVhttps://practicaldermatology.com/news/new-deuruxolitinib-data-be-presented-eadv/2468304/Sun Pharma will present new clinical data on the JAK1/JAK2 inhibitor deuruxolitinib at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands from September 25-28, the company announced. Deuruxolitinib, which Sun Pharma provides under the name LE
- Report: Nonsurgical Aesthetics Revenues Up 9%https://practicaldermatology.com/news/report-nonsurgical-aesthetics-revenues-9/2468303/Data and analytics solutions provider Guidepoint Qsight and investment banking and management consulting firm Skytale Group released a new report on the state of the aesthetics industry, highlighting the continued expansion of the US market. Combined nonsurgical revenues increased by 9% in
- Anti-C5a Antibody Vilobelimab for HS to Be Presented at EADVhttps://practicaldermatology.com/news/anti-c5a-antibody-vilobelimab-hs-be-presented-eadv/2468302/InflaRx N.V. announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, Netherlan